HighTide Therapeutics Inc (2511.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: Liping Liu
Listed since: Dec 22, 2023
Employees: 51

Market position

Day range

Current HK$3.28

HK$3.21HK$3.305

52-week range

Current HK$3.28

HK$1.80HK$4.72

Open: HK$3.30
Previous close: HK$3.445
Volume: 68.5K; 0.08× average
Average volume: 852.21K; Average daily volume
Market cap: 1.67B HKD
Beta: -0.27; Market reference 1
50-day average: HK$2.9076; +12.81% above average
200-day average: HK$3.0073; +9.07% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 1.17B CNY
P/E (TTM): -5.41×
P/B (TTM): 4.66×
P/S (TTM): 0×
EV / EBITDA: -5.25×
Earnings yield: -19.27%
Free cash flow yield: -13.14%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -79.76%
Return on assets: -44.41%
Return on invested capital: -45.45%

Financial health

Debt / equity: 0.41×
Current ratio: 5.41×
Altman Z-score: -4.32
Piotroski F-score: 2 of 9

Financial statements

Income trends

Operating income

−223.57M CNY+49.73%

Net income

−244.97M CNY+35.84%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	164.47M CNY	363.53M CNY	311.57M CNY	182.65M CNY	84.01M CNY
Selling, general, and administrative	59.1M CNY	81.23M CNY	136.67M CNY	43.43M CNY	48.06M CNY
Operating expenses	223.57M CNY	444.75M CNY	448.24M CNY	226.08M CNY	132.08M CNY
Interest income	10.23M CNY	27.65K CNY	26.83M CNY	3.55M CNY	964K CNY
Interest expense	2.3M CNY	1.53M CNY	442K CNY	426K CNY	4.53M CNY
Depreciation and amortization	1.41M CNY	1.01M CNY	537K CNY	409K CNY	276K CNY
Operating income	−223.57M CNY	−444.75M CNY	−448.24M CNY	−226.08M CNY	−132.08M CNY
Net income	−244.97M CNY	−381.79M CNY	−939.31M CNY	−190.24M CNY	−221.15M CNY